Spain pharma reforms, generic uptake and pricing debate

Timeline

1. 10 days ago

   [BUSINESS] 3 sources

   Spain's AESEG warns new drug pricing decree fails to stop generic price erosion

   AESEG says Spain's draft drug‑pricing decree fails to stop price erosion of generics, lacking safeguards and a cap on cuts, risking market viability and supply.

2. 17 days ago

   [HEALTH] 3 sources

   Spain advances generic, hybrid and biosimilar drug adoption and pricing reforms

   Spain's health ministry reports rapid growth of generic, hybrid and biosimilar medicines, while a new law introduces dynamic pricing and supply safeguards to improve affordability and access.

3. 20 days ago

   [BUSINESS] 2 sources

   Spain's research budget cap criticised as insufficient amid new health funding rollout

   Spain's research funding faces criticism as a €700 million cap is deemed insufficient, while the Ministry allocates €45.3 million to health research contracts and grants.

4. 24 days ago

   [HEALTH] 3 sources

   Spain's Health Secretary Padilla backs infectious disease specialty

   Spain’s health secretary Javier Padilla pledged a new infectious‑disease specialty and highlighted reforms making the country attractive for biotech investment.

5. 24 days ago

   [HEALTH] 2 sources

   Spain's generic drug push and Horizon Scanning forecast aim to sustain health system

   Spain's health ministry stresses generic drugs for cost savings and access, while Farmaindustria's Horizon Scanning forecasts 172 upcoming therapies to aid system planning and sustainability.

6. 28 days ago

   [HEALTH] 4 sources

   Novartis Spain launches 'Lleva la Delantera' breast cancer awareness campaign

   Novartis Spain unveiled the 'Lleva la Delantera' campaign in Madrid, uniting patients, associations and doctors to provide information, support and empowerment for women with breast cancer.

7. 30 days ago

   [HEALTH] 2 sources

   Spain's BioSim reports surge in oncology biosimilars

   BioSim's Horizon Scanning update highlights a wave of new oncology and immune‑mediated biosimilars, EU approvals and 96 Spanish clinical trials across 47 centres.

8. about 1 month ago

   [HEALTH] 2 sources

   Spain adds social‑value criteria to innovative drug assessments

   Spain's new health regulations will evaluate innovative medicines on clinical benefit and broader social value, including patient autonomy, reduced care costs and productivity gains.

9. about 1 month ago

   [HEALTH] 2 sources

   Spanish biotech firms win health innovation awards

   Spanish biotech firms Polar NanoPharma, Stablepharma and SmartBio Analytics win national awards for cancer nanomedicine, vaccine stability and bio‑analytical innovations, highlighting Spain's health‑tech growth

10. about 1 month ago

    [HEALTH] 6 sources

    Spain cuts drug funding delays as European pharma investment yields sixfold returns

    Spain shortens drug funding delays by 70 days, while a European pharma study shows a six‑fold economic return on €11.7 bn investment, boosting health outcomes and productivity.

11. about 1 month ago

    [HEALTH] 2 sources

    Spain to keep real drug prices confidential and draft conditional financing rules

    Spain’s coalition parties seek to keep real drug prices secret amid a Supreme Court case, while a draft decree proposes conditional and provisional funding for new medicines to manage uncertainty and costs.

12. about 2 months ago

    [BUSINESS] 5 sources

    Novartis positions Barcelona as global hub for biomedical innovation

    Novartis’ Barcelona Centres of Excellence employ 700 staff, blend AI with biotech, boost Spain’s pharma sector and support drug supply to 80+ countries.

13. about 2 months ago

    [HEALTH] 3 sources

    Novartis launches ‘Lleva la Delantera’ breast cancer empowerment campaign in Spain

    Novartis, together with Spanish breast‑cancer groups, launched the ‘Lleva la Delantera’ campaign in Spain to empower patients, improve information, and support shared decision‑making amid 38,000 annual cases.

14. about 2 months ago

    [HEALTH] 6 sources

    Spain's health innovation drive highlighted by Novartis

    Novartis highlights Spain's leading role in health innovation, with 962 clinical trials, €1.7 bn R&D spend and plans to cut patient wait times while addressing funding and bureaucratic hurdles.

15. about 2 months ago

    [HEALTH] 2 sources

    Spain launches health reforms on drug dispensing and tech assessment

    Spain enacted two health reforms: a decree overhauling drug dispensing and verification, and a new health‑technology assessment framework praised by Sanofi, Roche and Philips for greater transparency and value‑

16. 2 months ago

    [HEALTH] 2 sources

    Spain's health ministry drafts new drug pricing and funding rules

    Spain's health ministry proposes a draft law to include therapeutic, economic and social criteria in drug pricing and funding, while a Johnson & Johnson project highlights medicines as societal and economic le‑

17. 2 months ago

    [HEALTH] 2 sources

    Spain approves new health technology assessment decree and revamps drug copayment system

    Spain's new health technology assessment decree creates a unified HTA system with a transition year, while a progressive drug‑copayment reform reduces patient costs and may add a list of high‑value medicines, c

18. 3 months ago

    [HEALTH] 7 sources

    Spain introduces progressive pharmaceutical co‑payment tiers under new decree

    Spain's new decree adds income‑based tiers and caps to prescription drug co‑payments, costing €265 M.